EBS Emergent BioSolutions Inc.

Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences

Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences

GAITHERSBURG, Md., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the fourth quarter and early portion of the first quarter of 2019:

  • JP Morgan – 2018 CEO Conference Call Series

    Virtual/Conference Call (information to be provided by JP Morgan)

    November 13, 2018



  • Three Part Advisors – 2018 Southwest IDEAS Investor Conference

    Dallas, TX

    November 14-15, 2018



  • Piper Jaffray – 30th Annual Healthcare Conference

    New York, NY

    November 27-29, 2018



  • Mizuho – Global Mizuho Investor Conference

    New York, NY

    December 3, 2018



  • BMO Capital Markets – 2018 Prescriptions for Success Healthcare Conference

    New York, NY

    December 12, 2018



  • JP Morgan – 37th Annual Healthcare Conference

    San Francisco, CA

    January 7-10, 2019

Presentation dates and times will be updated on the Emergent website  under “Investors” as the information becomes available.

For these conferences, the company will be webcasting its presentation, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcasts will be available both live and by replay, accessible from the Emergent website.

About Emergent BioSolutions

Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. We aspire to be a Fortune 500 company recognized for protecting and enhancing life, driving innovation, and living our values. Additional information about the company may be found at . Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

Investor Contact:

Robert G. Burrows

Vice President, Investor Relations

240-631-3280

Media Contact:

Lynn Kieffer

Vice President, Corporate Communications

240-631-3391

EN
06/11/2018

Underlying

EBSEmergent BioSolutions Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financ...

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 Ad...

11h / 15m 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Announces New $50 Million Stock Repurchase Progr...

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company’s common stock on or before March 31, 2027. This authorization replaces the prior repurchase authorization which permitted Emergent to repurchase up to $50 million of company’s common stock by March 27, 2026. Under the prior authorization, Emergent repurchased $24.8 million shares. “In 2025, we were able to return value t...

11h / 19m 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Announces Approximately $140 Million in Contract...

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness WINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to support Canada’s biological threat preparedness and response infrastructure. The multiyear agreements, valued at up to approximately...

11h / 19m 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New D...

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks Approval will broaden the NARCAN® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication  GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN® Nasal Spray. T...

February 12, 2026 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Fina...

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025. Participants can access the conference call live via and also by visiting the page of Emergent’s website. To participate via telephone, please register in advance at this . Upon registration, all telephone participants will receive ...

February 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch